Brain cancer drug trial halted early

NCT ID NCT01068782

Summary

This study tested whether the drug cabozantinib could help control aggressive brain tumors that had returned after initial treatment. It involved 19 people with recurrent grade IV astrocytic tumors and tested four different dosing schedules to find the best balance of effectiveness and safety. The trial was terminated early by the sponsor for business reasons before any results on tumor response could be collected.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTIC TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Birmingham, Alabama, 35294, United States

  • Study site

    Encinitas, California, 92024, United States

  • Study site

    Pleasant Hill, California, 94523, United States

  • Study site

    Chicago, Illinois, 60611, United States

  • Study site

    Chicago, Illinois, 60637, United States

  • Study site

    Boston, Massachusetts, 02115, United States

  • Study site

    Detroit, Michigan, 48202, United States

  • Study site

    Minneapolis, Minnesota, 55407, United States

  • Study site

    Amherst, New York, 14226, United States

  • Study site

    Rochester, New York, 14642, United States

  • Study site

    Cleveland, Ohio, 44195, United States

  • Study site

    Hershey, Pennsylvania, 17033, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Dallas, Texas, 75426, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Charlottesville, Virginia, 22908, United States

  • Study site

    Seattle, Washington, 98122, United States

  • Study site

    Calgary, Alberta, Canada

  • Study site

    Montreal, Quebec, Canada

Conditions

Explore the condition pages connected to this study.